Excellent view Pete. Getting the most from prurisol would be making sure we get royalties for any future indications it gets used for. If we do get decent to excellent data I believe the plan (unofficially) is to sell it. It may be more likely that it'll be partnered with the new partner taking it over but we get the milestones and a decent upfront payment.
Thinking smaller office and less staff leans in that direction. Getting it done so kevetrin can move forward has been a goal for sure.
Will be a great day if we do see dent top line and BP takes on both prurisol and brilacidin at the same time.